Key terms
About VSTM
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest VSTM news
Apr 18
4:05pm ET
Verastem names John Hayslip as Chief Medical Officer
Apr 16
6:00am ET
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
Apr 12
7:00am ET
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
Apr 09
5:22pm ET
Verastem Releases Updated Corporate Presentation for Investors
Apr 04
7:31am ET
Verastem announces inducement grants under Nasdaq listing rule
Mar 19
6:18am ET
Verastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term Losses
Mar 16
12:30pm ET
Analysts’ Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)
Mar 16
2:02am ET
Verastem Inc. at a Crossroads: Navigating the Perilous Terrain of Patent Ownership and IP Rights
Mar 14
4:26pm ET
Verastem reports Q4 adjusted EPS ($1.10), consensus (62c)
Mar 11
1:10am ET
Analysts Are Bullish on These Healthcare Stocks: Wave Life Sciences (WVE), Dexcom (DXCM)
Mar 05
5:29pm ET
Verastem receives Orphan Drug Designation from FDA for avutometinib
Mar 05
8:53am ET
Verastem treatment of low grade serous ovarian cancer granted orphan designation
Jan 29
8:46pm ET
Buy Rating on Verastem: Strategic Execution and Promising Drug Pipeline Signal Market Opportunity
Jan 20
3:06am ET
Verastem Shareholders Approve Executive Option Exchange Plan
No recent press releases are available for VSTM
VSTM Financials
Key terms
Ad Feedback
VSTM Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
VSTM Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range